- Ørsted is having a rough year.
- Can sentiment recover?
For such a small country, Denmark punches far above its weight when it comes to producing blue-chip companies.
During the past year, the Copenhagen market’s leading light has been multinational pharma firm Novo Nordisk (DK:NOVO-B), whose semaglutide products have given it first-mover advantage in the weight-loss drug market bonanza. So fevered has the demand been for its products that the Danish central bank has had to keep interest rates artificially low, to stop the krone becoming overvalued.